Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Akebia's First Quarter 2026 Financial Results Conference Call.
Akebia Therapeutics Inc. (AKBA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 2,384,713 | $3,314,751 | +45% | 0% |
| 2. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,000,000 | $2,780,000 | 0.1% | |
| 3. | Renaissance Technologies Jim Simons | 1,833,128 | $2,548,048 | -49% | 0% |
| 4. | AQR Capital Management Cliff Asness | 1,792,620 | $2,491,742 | +178% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 1,390,067 | $1,932,194 | -71% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.25 | 69,270 | $86,587.50 | 3,367,064 | 2026-03-04 | Filing | |
| $3.43 | 5,800 | $19,894.00 | 29,731 | 2019-11-20 | Filing | |
| $3.52 | 15,000 | $52,800.00 | 28,700 | 2019-11-20 | Filing | |
| $3.58 | 27,000 | $96,660.00 | 37,000 | 2019-11-20 | Filing | |
| $3.44 | 50,000 | $172,000.00 | 887,732 | 2019-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.39 | 13,382 | $18,600.98 | 299,390 | 2026-02-02 | Filing | |
| $1.39 | 36,142 | $50,237.38 | 312,772 | 2026-02-02 | Filing | |
| $1.39 | 31,244 | $43,429.16 | 561,750 | 2026-02-02 | Filing | |
| $1.39 | 53,585 | $74,483.15 | 592,994 | 2026-02-02 | Filing | |
| $1.39 | 20,701 | $28,774.39 | 948,432 | 2026-02-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,693,296 | $25,983,682 | 0% | |
| 2. | 11,614,006 | $16,143,468 | 0% | |
| 3. | 11,166,710 | $15,521,727 | 0% | |
| 4. | 6,452,252 | $8,970,938 | 0% | |
| 5. | 3,602,827 | $5,007,930 | 0% |
News See All
10 Best Penny Stocks That Could Triple Your Money
In this article, we will take a look at the 10 best penny stocks that are currently offering more than 200% upside potential to investors.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript February 26, 2026Akebia Therapeutics, Inc. misses on earnings expectations.
Piper Sandler Lowers Akebia Therapeutics (AKBA) PT to $4 as Firm Updates Estimates Following Year-End Reports
Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the best growth stocks to buy for the next 20 years.
10 Best Growth Stocks to Buy for the Next 20 Years
On February 13, Chief Market Strategist at Carson Group Ryan Detrick and CEO of MCC Global Enterprises Michelle Caruso-Cabrera joined CNBC to discuss rising geopolitical tensions, tariff shifts, and whether...
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat
Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the cheap penny stocks to invest in. On December 1, Akebia Therapeutics announced the official establishment of its rare kidney disease pipeline.
11 Cheap Penny Stocks to Invest In
On December 17, Lale Akoner, Global Market Analyst at eToro, appeared on CNBC to suggest that she is observing capital moving away from high-multiple mega-cap stocks and toward small caps, cyclical sectors...
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Akebia's Third Quarter 2025 Financial Results Conference Call.
Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best multibagger penny stocks to buy according to analysts.
13 Best Multibagger Penny Stocks to Buy According to Analysts
It’s time to pivot towards micro and small-cap stocks as the US Federal Reserve prepares to cut interest rates.
Hedge Fund Resource Center